Christopher Liu
Stock Analyst at Lucid Capital
(3.70)
# 2,022
Out of 4,376 analysts
157
Total ratings
41.6%
Success rate
8.1%
Average return
Main Sectors:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRDF Cardiff Oncology | Maintained: Buy | $14 → $4 | $1.50 | +166.67% | 2 | Jun 5, 2026 | |
| NXTC NextCure | Maintained: Buy | $25 | $2.95 | +747.46% | 2 | Jun 2, 2026 | |
| SNSE Sensei Biotherapeutics | Initiated Coverage: Buy | $50 | $14.65 | +241.30% | 1 | May 28, 2026 | |
| ACTU Actuate Therapeutics | Maintained: Buy | $5 | $1.88 | +165.96% | 1 | May 18, 2026 | |
| RLMD Relmada Therapeutics | Initiated Coverage: Buy | $14 | $5.95 | +135.29% | 1 | Mar 2, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $42 → $6 | $2.89 | +107.61% | 2 | Feb 4, 2026 | |
| ANL Adlai Nortye | Initiated Coverage: Buy | $11 | $10.18 | +8.05% | 1 | Jan 29, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $50 | $17.20 | +190.70% | 1 | Dec 15, 2025 | |
| IPHA Innate Pharma | Initiated Coverage: Buy | $8 | $1.77 | +352.00% | 1 | Oct 23, 2025 | |
| LYEL Lyell Immunopharma | Initiated Coverage: Buy | $20 | $11.97 | +67.08% | 1 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $3.32 | +171.08% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $2.93 | +241.30% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $1.65 | n/a | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $19 → $37 | $52.70 | n/a | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 → $36 | $14.64 | n/a | 20 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $9.54 | n/a | 1 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $3.03 | n/a | 1 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $28.29 | n/a | 7 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $31.02 | n/a | 28 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $13.52 | n/a | 4 | Feb 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $69 | $90.95 | n/a | 7 | Jan 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.85 | n/a | 14 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $77 | $7.42 | n/a | 22 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $16.37 | n/a | 12 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $13 | $10.61 | n/a | 2 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $34.19 | n/a | 2 | Aug 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $27 | $6.03 | n/a | 2 | Aug 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $22.75 | n/a | 2 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.4274 | n/a | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $10.83 | n/a | 2 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.27 | n/a | 1 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.001 | n/a | 2 | Jul 6, 2018 |
Cardiff Oncology
Jun 5, 2026
Maintained: Buy
Price Target: $14 → $4
Current: $1.50
Upside: +166.67%
NextCure
Jun 2, 2026
Maintained: Buy
Price Target: $25
Current: $2.95
Upside: +747.46%
Sensei Biotherapeutics
May 28, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $14.65
Upside: +241.30%
Actuate Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $5
Current: $1.88
Upside: +165.96%
Relmada Therapeutics
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $5.95
Upside: +135.29%
Tvardi Therapeutics
Feb 4, 2026
Upgraded: Buy
Price Target: $42 → $6
Current: $2.89
Upside: +107.61%
Adlai Nortye
Jan 29, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $10.18
Upside: +8.05%
Ascentage Pharma Group International
Dec 15, 2025
Initiated Coverage: Buy
Price Target: $50
Current: $17.20
Upside: +190.70%
Innate Pharma
Oct 23, 2025
Initiated Coverage: Buy
Price Target: $8
Current: $1.77
Upside: +352.00%
Lyell Immunopharma
Sep 26, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $11.97
Upside: +67.08%
Sep 18, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $3.32
Upside: +171.08%
Jul 21, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $2.93
Upside: +241.30%
May 28, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $1.65
Upside: n/a
May 14, 2025
Maintained: Hold
Price Target: $19 → $37
Current: $52.70
Upside: n/a
Apr 9, 2025
Maintained: Buy
Price Target: $28 → $36
Current: $14.64
Upside: n/a
Feb 26, 2025
Initiated Coverage: Buy
Price Target: $18
Current: $9.54
Upside: n/a
Jan 27, 2025
Maintained: Buy
Price Target: $20
Current: $3.03
Upside: n/a
Feb 21, 2024
Reiterated: Buy
Price Target: $50
Current: $28.29
Upside: n/a
Feb 20, 2024
Maintained: Buy
Price Target: n/a
Current: $31.02
Upside: n/a
Feb 13, 2024
Maintained: Buy
Price Target: $18
Current: $13.52
Upside: n/a
Jan 8, 2024
Maintained: Hold
Price Target: $69
Current: $90.95
Upside: n/a
Dec 13, 2023
Reiterated: Buy
Price Target: $14
Current: $3.85
Upside: n/a
Dec 8, 2023
Reiterated: Buy
Price Target: $70 → $77
Current: $7.42
Upside: n/a
Nov 9, 2023
Maintained: Hold
Price Target: $5
Current: $16.37
Upside: n/a
Aug 9, 2018
Rated: Buy
Price Target: $13
Current: $10.61
Upside: n/a
Aug 2, 2018
Rated: Hold
Price Target: n/a
Current: $34.19
Upside: n/a
Aug 2, 2018
Rated: Buy
Price Target: $27
Current: $6.03
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $22.75
Upside: n/a
Jul 27, 2018
Rated: Hold
Price Target: n/a
Current: $0.4274
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $10.83
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $1.27
Upside: n/a
Jul 6, 2018
Maintained: Hold
Price Target: n/a
Current: $0.001
Upside: n/a